Publications by authors named "Corbacioglu S"

The clinical policy of the Emergency Medicine Association of Türkiye (EMAT) provides guidance on the use of tranexamic acid (TXA) in emergency settings. TXA, an antifibrinolytic drug, is used to control bleeding by inhibiting plasminogen. Its applications have expanded from hemophilia and severe menstrual bleeding to include various forms of trauma and surgery-related bleeding.

View Article and Find Full Text PDF
Article Synopsis
  • Treosulfan is an important treatment in allogeneic haematopoietic stem cell transplantation (allo-HSCT) for children, offering lower toxicity than traditional drugs.
  • Researchers studied the effects of treosulfan on 83 pediatric patients to see how it impacts survival, graft failure, and graft-versus-host disease.
  • The results showed no significant correlation between treosulfan exposure and clinical outcomes or toxicity, indicating that standardized dosing is effective for pediatric allo-HSCT.
View Article and Find Full Text PDF

RNA editing is a highly conserved process. Adenosine deaminase acting on RNA (ADAR) mediated deamination of adenosine (A-to-I editing) is associated with human disease and immune checkpoint control. Functional implications of A-to-I editing are currently of broad interest to academic and industrial research as underscored by the fast-growing number of clinical studies applying base editors as therapeutic tools.

View Article and Find Full Text PDF

Objective: This study aimed to investigate the relationship between procalcitonin (PCT) kinetic and estimated glomerular filtration rates (eGFR) in critically ill patients who had Gram-negative primary bloodstream infection (GN-BSI) and responded to the antimicrobial therapy.

Materials And Methods: This single-centered study was retrospective and observational. Critically ill GN-BSI patients over 18 years old who had clinical and microbiological responses to antibiotic treatment were included in the study.

View Article and Find Full Text PDF
Article Synopsis
  • * A significant number of respondents (67.0%) felt that early diagnosis was challenging, but many (75.8%) found the new 2023 EBMT diagnostic criteria useful and easy to apply.
  • * Key risk factors for VOD/SOS included second allo-HCT, pre-existing liver disease, and prior use of antibody-drug conjugates, with varied preferences on when to start treatment.
View Article and Find Full Text PDF

Congenital amegakaryocytic thrombocytopenia is a rare, inherited bone marrow failure syndrome. Allogeneic haematopoietic stem cell transplantation (allo-HSCT) is currently the only curative treatment. In this retrospective study, we analysed 66 patients with allo-HSCT, reported in the European Society for Blood and Marrow Transplantation (EBMT) registry.

View Article and Find Full Text PDF

The COVID-19 pandemic affected daily life significantly and had massive consequences for healthcare systems with tremendous regional differences. This retrospective study aimed to investigate whether the pandemic and resulting societal changes impacted the diagnosis of pediatric malignancies in a distinct region. Pediatric cancer cases in Bavaria (2016-2021) and SARS-CoV-2 proceedings during the peak phase of the pandemic (2020-2021) were retrospectively analyzed.

View Article and Find Full Text PDF

Allogeneic hematopoietic stem cell transplantation (HSCT) is the only established curative option for Fanconi anemia (FA)-associated bone marrow failure (BMF)/aplastic anemia (AA) and acute myeloid leukemia (AML)/myelodysplastic syndrome (MDS). We performed a retrospective multicenter study on 813 children with FA undergoing first HSCT between 2010 and 2018. Median duration of follow-up was 3.

View Article and Find Full Text PDF

Background: Neuroblastoma is the most common extracranial solid tumour in children. Relapsed or refractory neuroblastoma is associated with a poor outcome. We assessed the combination of irinotecan-temozolomide and dasatinib-rapamycin (RIST) in patients with relapsed or refractory neuroblastoma.

View Article and Find Full Text PDF

Background: The term gliomatosis cerebri (GC), a radiology-defined highly infiltrating diffuse glioma, has been abandoned since molecular GC-associated features could not be established.

Methods: We conducted a multinational retrospective study of 104 children and adolescents with GC providing comprehensive clinical and (epi-)genetic characterization.

Results: Median overall survival (OS) was 15.

View Article and Find Full Text PDF
Article Synopsis
  • Exagamglogene autotemcel (exa-cel) is a nonviral cell therapy utilizing CRISPR-Cas9 gene editing to increase fetal hemoglobin production in patients with sickle cell disease.
  • A phase 3 study involved 44 patients aged 12 to 35 with a history of severe vaso-occlusive crises; patients received edited stem cells after myeloablative conditioning.
  • Results showed 97% of patients were free from vaso-occlusive crises and 100% avoided hospitalization for over 12 months, with a safety profile similar to standard treatments.
View Article and Find Full Text PDF
Article Synopsis
  • Exagamglogene autotemcel (exa-cel) is a novel cell therapy using CRISPR-Cas9 gene editing to boost fetal hemoglobin production in patients with transfusion-dependent β-thalassemia.
  • In a phase 3 study, 52 patients aged 12 to 35 underwent treatment with exa-cel after myeloablative conditioning, and 91% achieved transfusion independence for at least 12 months.
  • The therapy showed promising results with high mean total and fetal hemoglobin levels, a favorable safety profile, and no serious adverse events like deaths or cancers reported during the follow-up period.
View Article and Find Full Text PDF

This retrospective study evaluated 35 children (median age 5.2 years; range 0.4-18) with myelofibrosis (MF), including 33 with primary myelofibrosis and 2 with secondary myelofibrosis transplanted from matched sibling donor (MSD) (n = 17) or non-MSD (n = 18) between 2000 and 2022.

View Article and Find Full Text PDF

Background/aim: The indications for neuroimaging in emergency department (ED) patients presenting with seizures have not been clearly defined. In this study, we aimed to investigate the findings that may influence the emergency management of patients with seizures undergoing brain computed tomography (CT) and the factors that influence these findings.

Material And Methods: This is a retrospective, single-center study.

View Article and Find Full Text PDF
Article Synopsis
  • Haploidentical stem cell transplantation (haplo-SCT) helps children with a genetic problem that affects their bone marrow when they can’t find a matching donor.
  • A study looked at 162 patients and found that the best type of T-cell removal, called TCRαβ/CD19 depletion, led to better survival rates and fewer serious side effects.
  • Overall, the study shows that haplo-SCT is a safe option and that the TCRαβ/CD19 method could give kids with these conditions a better chance to live without severe complications.
View Article and Find Full Text PDF

Cell and gene therapy poses evolving challenges. The current article summarizes the discussions held by European Regional Committee of the International Society for Cell & Gene Therapy and the European Society for Blood and Marrow Transplantation (EBMT) on the current challenges in this field, focusing on the European setting. This article emphasizes the imperative assessment of real-world cell and gene therapy activity, advocating for expanded registries beyond hematopoietic transplantation and chimeric antigen receptor-T-cell therapy.

View Article and Find Full Text PDF

Peripheral T-cell lymphomas (PTCL) other than anaplastic large-cell lymphoma are rare in children, and the role of hematopoietic stem cell transplantation (HSCT) has not been clarified yet. In a retrospective analysis of registry-data of the European Society for Blood and Marrow Transplantation we analyzed 55 patients aged < 18 years who received allogeneic (N = 46) or autologous (N = 9) HSCT for PTCL. Median age at HSCT was 13.

View Article and Find Full Text PDF

We performed a retrospective analysis on 124 patients with transfusion-dependent thalassemia who were registered in the German pediatric registry for stem cell transplantation. All patients underwent first allogeneic hematopoietic stem cell transplantation (HSCT) between 2011 and 2020 and belonged mainly to Pesaro risk class 1-2. Four-year overall (OS) and thalassemia-free survival (TFS) were 94.

View Article and Find Full Text PDF
Article Synopsis
  • Kids with a type of cancer called AML have different risk levels based on genetic tests, which can affect their treatment options.
  • In a study of 845 young patients who had a stem cell transplant, those with certain genetic abnormalities did better overall than others.
  • This means that knowing a patient's specific genetic risks can help doctors predict how well they might do after treatment.
View Article and Find Full Text PDF
Article Synopsis
  • In kids with acute myeloid leukemia (AML) who don't have a sibling that is a perfect match for a donor, doctors can use other types of donors.
  • This study looked at how well kids with AML did after receiving stem cell transplants from two different types of donors from 2011 to 2021.
  • It found that while one type of transplant (from a haploidentical donor) had a higher risk of certain complications, both transplant types showed similar success rates in keeping the leukemia away and overall survival after two years.
View Article and Find Full Text PDF

β-thalassemia is a monogenic disease that results in varying degrees of anemia. In the most severe form, known as transfusion-dependent β-thalassemia (TDT), the clinical hallmarks are ineffective erythropoiesis and a requirement of regular, life-long red blood cell transfusions, with the development of secondary clinical complications such as iron overload, end-organ damage, and a risk of early mortality. With the exception of allogeneic hematopoietic cell transplantation, current treatments for TDT address disease symptoms and not the underlying cause of disease.

View Article and Find Full Text PDF

This review article provides a concise guide to interpreting receiver operating characteristic (ROC) curves and area under the curve (AUC) values in diagnostic accuracy studies. ROC analysis is a powerful tool for assessing the diagnostic performance of index tests, which are tests that are used to diagnose a disease or condition. The AUC value is a summary metric of the ROC curve that reflects the test's ability to distinguish between diseased and nondiseased individuals.

View Article and Find Full Text PDF